Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce results for the
third quarter ended September 30, 2008 after market trading hours on
Wednesday, November 5, 2008.
A quarterly conference call to discuss third quarter 2008 financial
results will be held on Wednesday, November 5, 2008 at 5:30 p.m. Boston
time. In addition, management may answer questions concerning business
and financial developments and trends, the Company's view on earnings
forecasts, and other business and financial matters affecting the
Company. Some of the information to be presented on the call or provided
in response to questions may contain information that has not previously
been disclosed.
The conference call will be simultaneously broadcast over the Internet
and can be accessed through the Harvard Bioscience, Inc. website. To
listen to the conference call, log on to our website at www.harvardbioscience.com
and click on the Earnings Call icon. Financial and other statistical
information presented on the call, including our earnings release, will
also be available on the investor relations section of our website.
Click on the investor relations’ button and
then click on the press release or web cast icon, as appropriate. If you
are unable to listen to the live web cast, the call will be archived in
the investor relations section of our web site. The live conference call
is also accessible by dialing 800-659-1966 and referencing the pass code
of "37309231”. A
replay of this conference call will be available from 7:30 p.m. on
November 5, 2008 through November 12, 2008 and will be accessible by
dialing 888-286-8010 and referencing the pass code of "67712013”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a
broad range of specialized products, primarily scientific instruments
and apparatus, used to advance life science research at pharmaceutical
and biotechnology companies, universities and government laboratories
worldwide. HBIO sells its products to thousands of researchers in over
100 countries primarily through its 900 page catalog (and various other
specialty catalogs), its website and through its distributors, including
GE Healthcare, Thermo Fisher Scientific and VWR. HBIO has sales and
manufacturing operations in the United States, the United Kingdom,
Germany and Spain with additional facilities in France and Canada. For
more information, please visit www.harvardbioscience.com.
The statements made in this press release that are not statements of
historical fact are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934.
These statements involve known
and unknown risks, uncertainties and other factors that may cause the
Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements.
Factors that may cause the Company’s
actual results, performance or achievements to differ materially from
those in the forward-looking statements include, but are not limited to,
those factors set forth under the heading "Item
1A. Risk Factors” in the Company’s
Annual Report on Form 10-K/A for the fiscal year ended December 31, 2007
or described in the Company’s other public
filings. The Company’s results may also be
affected by factors of which the Company is not currently aware.
The
Company may not update these forward-looking statements, even though its
situation may change in the future, unless it has obligations under the
federal securities laws to update and disclose material developments
related to previously disclosed information.
